MX2023004763A - Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. - Google Patents
Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal.Info
- Publication number
- MX2023004763A MX2023004763A MX2023004763A MX2023004763A MX2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A
- Authority
- MX
- Mexico
- Prior art keywords
- pro
- muscular atrophy
- spinal muscular
- myostatin antibody
- latent myostatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105850P | 2020-10-26 | 2020-10-26 | |
| US202063106172P | 2020-10-27 | 2020-10-27 | |
| US202163200955P | 2021-04-05 | 2021-04-05 | |
| US202163201157P | 2021-04-15 | 2021-04-15 | |
| US202163202317P | 2021-06-06 | 2021-06-06 | |
| US202163202372P | 2021-06-08 | 2021-06-08 | |
| US202163202900P | 2021-06-29 | 2021-06-29 | |
| US202163260725P | 2021-08-30 | 2021-08-30 | |
| US202163261398P | 2021-09-20 | 2021-09-20 | |
| PCT/US2021/056517 WO2022093724A1 (en) | 2020-10-26 | 2021-10-25 | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004763A true MX2023004763A (es) | 2023-05-09 |
Family
ID=78622120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004763A MX2023004763A (es) | 2020-10-26 | 2021-10-25 | Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240002490A1 (enExample) |
| EP (2) | EP4729069A1 (enExample) |
| JP (1) | JP2023549455A (enExample) |
| KR (1) | KR20230095998A (enExample) |
| CN (1) | CN116390756A (enExample) |
| AU (1) | AU2021369471A1 (enExample) |
| CA (1) | CA3193909A1 (enExample) |
| ES (1) | ES3058087T3 (enExample) |
| IL (1) | IL302132A (enExample) |
| MX (1) | MX2023004763A (enExample) |
| PL (1) | PL4232151T3 (enExample) |
| TW (1) | TW202233234A (enExample) |
| WO (1) | WO2022093724A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| DK4518970T3 (da) | 2022-05-04 | 2026-04-07 | Scholar Rock Inc | Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi |
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2026076383A1 (en) | 2024-10-06 | 2026-04-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| JP2010523684A (ja) | 2007-04-12 | 2010-07-15 | パラテック ファーマシューティカルズ インコーポレイテッド | テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法 |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| NZ789269A (en) | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
-
2021
- 2021-10-25 AU AU2021369471A patent/AU2021369471A1/en active Pending
- 2021-10-25 US US18/250,489 patent/US20240002490A1/en active Pending
- 2021-10-25 CA CA3193909A patent/CA3193909A1/en active Pending
- 2021-10-25 EP EP25209770.4A patent/EP4729069A1/en active Pending
- 2021-10-25 CN CN202180071515.9A patent/CN116390756A/zh active Pending
- 2021-10-25 ES ES21807468T patent/ES3058087T3/es active Active
- 2021-10-25 MX MX2023004763A patent/MX2023004763A/es unknown
- 2021-10-25 PL PL21807468.0T patent/PL4232151T3/pl unknown
- 2021-10-25 JP JP2023524333A patent/JP2023549455A/ja active Pending
- 2021-10-25 WO PCT/US2021/056517 patent/WO2022093724A1/en not_active Ceased
- 2021-10-25 KR KR1020237016836A patent/KR20230095998A/ko active Pending
- 2021-10-25 TW TW110139566A patent/TW202233234A/zh unknown
- 2021-10-25 IL IL302132A patent/IL302132A/en unknown
- 2021-10-25 EP EP21807468.0A patent/EP4232151B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL302132A (en) | 2023-06-01 |
| US20240002490A1 (en) | 2024-01-04 |
| AU2021369471A1 (en) | 2023-06-15 |
| PL4232151T3 (pl) | 2026-02-23 |
| CA3193909A1 (en) | 2022-05-05 |
| TW202233234A (zh) | 2022-09-01 |
| AU2021369471A9 (en) | 2024-02-08 |
| KR20230095998A (ko) | 2023-06-29 |
| EP4232151A1 (en) | 2023-08-30 |
| EP4729069A1 (en) | 2026-04-22 |
| CN116390756A (zh) | 2023-07-04 |
| EP4232151B1 (en) | 2025-10-22 |
| JP2023549455A (ja) | 2023-11-27 |
| ES3058087T3 (en) | 2026-03-06 |
| WO2022093724A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004763A (es) | Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. | |
| MX2020010603A (es) | Extracto de cáñamo para tratamiento de dolor en animales. | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| SG161259A1 (en) | Method for treatment of constipation-predominant irritable bowel syndrome | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| MX2020012018A (es) | Composiciones para el tratamiento de condiciones de la piel. | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| PT2126049E (pt) | Anticorpos contra citomegalovírus humano (hcmv) | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| MX2024011278A (es) | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| PH12021552135A1 (en) | Methods of treating al amyloidosis | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2025008017A (es) | Uso de moduladores del receptor gabaa para el tratamiento del dolor | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| WO2022173714A3 (en) | Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof | |
| TW200833710A (en) | Treatment for spinal muscular atrophy | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| MX2021009189A (es) | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. | |
| WO2021257695A8 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus |